Sentinel Blood — Monitoring for blood-based contexts.
SENTINEL · MONITORING FOR BLOOD-BASED CONTEXTS
Sentinel Blood is continuous monitoring for blood-based and haematological cancers on active treatment. It follows disease-specific molecular markers over time, so your team can see whether treatment is working and respond early if the picture changes.
2 · What it monitors
Condition-appropriate molecular markers — for example markers such as NPM1 or BCR-ABL1, or B-cell clonality signals, where relevant — tracked over time from a blood draw, each result read against your baseline.
3 · How it works
Baseline → Scheduled draws → Trend interpretation → Clinician review
Baseline
Establish your molecular starting point.
Scheduled draws
Monitoring on your chosen Track (2 / 4 / 6 per year).
Trend interpretation
The engine reads the direction of travel, not just one value.
Clinician review
A meaningful change triggers KPCIRC review and a plan.
4 · Honest limits
We believe in transparency about what a test can and cannot do.
Monitoring shows trends and can flag change early, but it does not replace your haematologist's assessment or scheduled testing, and no single result should be read in isolation. Decisions are made by your clinical team.
TERMINOLOGY ON THIS PAGE
The words you will see, in plain language
Sentinel Blood is a genomic (DNA-based) test offered for use by qualified healthcare professionals. It is intended to support — not replace — clinical judgement, and must be interpreted alongside your full clinical history, other investigations, and applicable guidelines.
- • A result is not a diagnosis and does not by itself decide treatment.
- • A "not detected" or normal result does not rule out cancer or a genetic change.
- • Not all cancers release enough DNA into blood to be detected.
- • The test does not guarantee access to any medicine, its regulatory approval, insurance cover, or that a therapy will work.
- • Sample-collection kits are for use by qualified phlebotomists only — not for self-testing or self-sampling.
- • Confirmatory testing may be required.
Regulatory status (India). OnKommon's registration of its genomic tests as in-vitro diagnostic (IVD) medical devices with the Central Drugs Standard Control Organisation (CDSCO) is in progress (IVD class pending). Sequencing and variant calling are performed by an accredited laboratory partner (College of American Pathologists — CAP-accredited; ISO 15189) following international guidelines (ACMG/AMP/ASCO/CAP) using a CE-IVD certified variant database. The OnKommon interpretation engine is provided for research and decision-support use. Marketing follows the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 and applicable Indian advertising standards.
Take the next step
Every OnKommon page offers three ways forward. Choose the one that fits where you are today.
Book a free Blueprint Consultation
A no-obligation conversation with our care team, arranged through KPCIRC, to map your situation and the right starting point.
Book now →Free WhatsApp guidance (Signal)
A 4-hour triage reply to your first question, at no cost.
Start WhatsApp triage →